**Supplemental Material - The impact of autocancellation of uncollected *Clostridioides difficile* specimens after 24 hours on reported healthcare-associated infections: A quality improvement intervention**

**Table of Contents**

[**Supplemental Table S1: *Clostridioides difficile* orders and order outcome among inpatients during implementation of a 24-hour electronic health record autocancellation for uncollected specimens.** 2](#_Toc133912520)

[**Supplemental Table S2: Reported *Clostridioides difficile* healthcare-associated infection rates per 10,000 patient days, facilities A and B, 2021-2022** 3](#_Toc133912521)

[**Supplemental Table S3: Reported *Clostridioides difficile* healthcare-associated infection rates per 10,000 patient days, facilities C-Q, 2021-2022** 4](#_Toc133912522)

[**Supplemental Table S4: Percent positivity of *Clostridioides difficile* tests completed before and after implementation of a 24-hour autocancellation** 5](#_Toc133912523)

[**Supplemental Table S5: Order rate per 10,000 patient days of *Clostridioides difficile* tests before and after implementation of a 24-hour autocancellation** 6](#_Toc133912524)

[**Supplemental Table S6: Completed test rate per 10,000 patient days of *Clostridioides difficile* before and after implementation of a 24-hour autocancellation** 7](#_Toc133912525)

[**Supplemental Figure S1: Timing of retesting of autocanceled *Clostridioides difficile* orders during the intervention period** 8](#_Toc133912526)

[**Supplemental Table S7: 30-day retesting outcomes following autocanceled *Clostridioides difficile* orders during the intervention period** 9](#_Toc133912527)

[**Supplemental Table S8: Reasons *Clostridioides difficile* autocanceled orders did not have a retest within 30 days** 10](#_Toc133912528)

# **Supplemental Table S1: *Clostridioides difficile* orders and order outcome among inpatients during implementation of a 24-hour electronic health record autocancellation for uncollected specimens.**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Facility** | **Order outcome** | | | | | | | | **Total** |
| **Autocanceled** | | **Provider canceled** | | **Rejected by lab** | | **Completed** | |
| A | 398 | 16.2% | 775 | 31.6% | 43 | 1.8% | 1236 | 50.4% | 2452 |
| B | 254 | 15.6% | 351 | 21.5% | 11 | 0.7% | 1017 | 62.3% | 1633 |
| C | 81 | 19.9% | 56 | 13.7% | 3 | 0.7% | 268 | 65.7% | 408 |
| D | 83 | 24.8% | 41 | 12.2% | 9 | 2.7% | 202 | 60.3% | 335 |
| E | 46 | 19.4% | 53 | 22.4% | 6 | 2.5% | 132 | 55.7% | 237 |
| F | 60 | 27.8% | 50 | 23.1% | 1 | 0.5% | 105 | 48.6% | 216 |
| G | 15 | 9.8% | 34 | 22.2% | 1 | 0.7% | 103 | 67.3% | 153 |
| H | 27 | 22.5% | 25 | 20.8% | 1 | 0.8% | 67 | 55.8% | 120 |
| I | 18 | 15.4% | 12 | 10.3% | 2 | 1.7% | 85 | 72.6% | 117 |
| J | 25 | 22.7% | 8 | 7.3% | 8 | 7.3% | 69 | 62.7% | 110 |
| K | 40 | 37.4% | 9 | 8.4% | 0 | 0.0% | 58 | 54.2% | 107 |
| L | 6 | 8.6% | 10 | 14.3% | 2 | 2.9% | 52 | 74.3% | 70 |
| M | 16 | 25.8% | 6 | 9.7% | 1 | 1.6% | 39 | 62.9% | 62 |
| N | 10 | 22.7% | 1 | 2.3% | 0 | 0.0% | 33 | 75.0% | 44 |
| O | 5 | 31.3% | 1 | 6.3% | 0 | 0.0% | 10 | 62.5% | 16 |
| P | 5 | 41.7% | 1 | 8.3% | 1 | 8.3% | 5 | 41.7% | 12 |
| Q | 1 | 11.1% | 0 | 0.0% | 0 | 0.0% | 8 | 88.9% | 9 |
| **Total** | **1090** | 17.9% | **1433** | 23.5% | **89** | 1.5% | **3489** | 57.2% | **6101** |

*Note: intervention period for facilities A and B, 11/1/2021-7/31/2022; intervention period for facilities C-Q, 4/1/2022-7/31/2022.*

# **Supplemental Table S2: Reported *Clostridioides difficile* healthcare-associated infection rates per 10,000 patient days, facilities A and B, 2021-2022**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Facility** | **2021** | | | | | | | | **2022** | | | | | | |
| **May** | **Jun** | **Jul** | **Aug** | **Sep** | **Oct** | **Nov** | **Dec** | **Jan** | **Feb** | **Mar** | **Apr** | **May** | **Jun** | **Jul** |
| A | 8.88 | 5.40 | 8.88 | 7.12 | 6.37 | 6.22 | 8.25 | 6.37 | 7.35 | 9.82 | 7.68 | 8.63 | 11.87 | 5.22 | 8.37 |
| B | 13.47 | 9.37 | 5.64 | 13.18 | 6.56 | 8.68 | 14.11 | 12.80 | 10.29 | 5.72 | 7.94 | 9.30 | 9.00 | 7.27 | 10.23 |

# **Supplemental Table S3: Reported *Clostridioides difficile* healthcare-associated infection rates per 10,000 patient days, facilities C-Q, 2021-2022**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Facility** | **2021** | | | **2022** | | | | | | |
| **Oct** | **Nov** | **Dec** | **Jan** | **Feb** | **Mar** | **Apr** | **May** | **Jun** | **Jul** |
| C | 3.81 | 9.96 | 3.92 | 5.28 | 10.90 | 5.48 | 4.51 | 4.16 | 8.36 | 9.80 |
| D | 6.42 | 13.00 | 5.75 | 5.12 | 1.37 | 5.04 | 5.28 | 6.43 | 4.46 | 8.24 |
| E | 15.40 | 7.78 | 10.39 | 7.42 | 2.81 | 5.04 | 8.42 | 7.88 | 15.67 | 8.17 |
| F | 2.18 | 8.45 | 2.14 | 2.00 | 8.20 | 14.10 | 5.96 | 5.58 | 11.38 | 8.20 |
| G | 3.18 | 2.09 | 3.62 | 0.00 | 4.06 | 3.68 | 1.93 | 0.00 | 8.39 | 5.60 |
| H | 2.79 | 3.19 | 6.25 | 13.75 | 6.98 | 3.13 | 5.93 | 15.84 | 3.12 | 6.31 |
| I | 3.74 | 1.80 | 6.95 | 6.92 | 1.96 | 0.00 | 6.00 | 1.90 | 3.91 | 0.00 |
| J | 25.61 | 8.55 | 12.52 | 4.45 | 5.64 | 10.09 | 10.47 | 0.00 | 4.96 | 14.33 |
| K | 0.00 | 12.95 | 0.00 | 12.20 | 38.83 | 0.00 | 21.23 | 0.00 | 0.00 | 0.00 |
| L | 9.27 | 6.83 | 6.21 | 6.02 | 15.85 | 0.00 | 8.63 | 9.89 | 0.00 | 0.00 |
| M | 0.00 | 0.00 | 15.52 | 0.00 | 9.51 | 0.00 | 0.00 | 10.10 | 0.00 | 8.57 |
| N | 0.00 | 0.00 | 0.00 | 0.00 | 15.60 | 14.27 | 0.00 | 0.00 | 16.16 | 0.00 |
| O | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| P | 44.74 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Q | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |

# **Supplemental Table S4: Percent positivity of *Clostridioides difficile* tests completed before and after implementation of a 24-hour autocancellation**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Facility** | **Pre-intervention 5.1.21 – 10.31.21** | | | **Intervention 11.1.22 – 7.31.22** | | | **Change in Percent Positivity (95%CI)** | **P-value** |
| **Positive** | **Total Tests Completed** | **Percent Positivity** | **Positive** | **Total Tests Completed** | **Percent Positivity** |
| A | 148 | 1164 | 12.7% | 180 | 1236 | 14.6% | 1.8% (-0.9 – 4.6) | 0.19 |
| B | 135 | 873 | 15.5% | 158 | 1017 | 15.5% | 0.1% (-3.2 – 3.3) | 0.97 |
| **Total** | **283** | **2037** | **13.9%** | **338** | **2253** | **15.0%** | **1.1% (-1.0 – 3.2)** | **0.30** |
|  | | | | | | | |  |
| **Facility** | **Pre-intervention 10.1.21 – 3.31.22** | | | **Intervention 4.1.22 – 7.31.22** | | | **Change in Percent Positivity (95% CI)** | **P-value** |
| **Positive** | **Total Tests Completed** | **Percent Positivity** | **Positive** | **Total Tests Completed** | **Percent Positivity** |
| C | 85 | 432 | 19.7% | 47 | 268 | 17.5% | -2.1% (-8.0 – 3.8) | 0.48 |
| D | 67 | 377 | 17.8% | 52 | 202 | 25.7% | 8.0% (0.8 – 15.1) | 0.02 |
| E | 36 | 242 | 14.9% | 23 | 132 | 17.4% | 2.5% (-5.3 – 10.4) | 0.52 |
| F | 44 | 215 | 20.5% | 18 | 105 | 17.1% | -3.3% (-12.3 – 5.7) | 0.48 |
| G | 17 | 183 | 9.3% | 23 | 103 | 22.3% | 13.0% (4.0 – 22.1) | 0.002 |
| H | 21 | 85 | 24.7% | 13 | 67 | 19.4% | -5.3% (-18.5 – 7.9) | 0.44 |
| I | 30 | 169 | 17.8% | 14 | 85 | 16.5% | -1.3% (-11.0 – 8.5) | 0.80 |
| J | 28 | 123 | 22.8% | 14 | 69 | 20.3% | -2.5% (-14.5 – 9.6) | 0.69 |
| K | 16 | 127 | 12.6% | 6 | 58 | 10.3% | -2.3% (-12.0 – 7.5) | 0.66 |
| L | 27 | 141 | 19.1% | 8 | 52 | 15.4% | -3.8% (-15.5 – 8.0) | 0.55 |
| M | 10 | 74 | 13.5% | 9 | 39 | 23.1% | 9.6% (-5.8 – 24.9) | 0.20 |
| N | 10 | 62 | 16.1% | 6 | 33 | 18.2% | 2.1% (-14.0 – 18.1) | 0.80 |
| O | 2 | 10 | 20.0% | 1 | 10 | 10.0% | -10.0% (-41.0 – 21.0) | 0.53 |
| P | 6 | 20 | 30.0% | 1 | 5 | 20.0% | -10.0% (-50.4 – 30.4) | 0.66 |
| Q | 1 | 9 | 11.1% | 0 | 8 | 0.0% | -11.1% (-31.6 – 9.4) | 0.33 |
| **Total** | **400** | **2269** | **17.6%** | **235** | **1236** | **19.0%** | **1.4% (-1.3 – 4.1)** | **0.31** |

# **Supplemental Table S5: Order rate per 10,000 patient days of *Clostridioides difficile* tests before and after implementation of a 24-hour autocancellation**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Facility | **Pre-intervention 5.1.21 - 10.31.21** | | | **Intervention 11.1.22 - 7.31.22** | | |
| Total Orders | Patient days | Order rate per 10,000 patient days | Total Orders | Patient days | Order rate per 10,000 patient days |
| A | 1857 | 114578 | 162.07 | 2452 | 153575 | 159.66 |
| B | 1242 | 73812 | 168.27 | 1633 | 101855 | 160.33 |
| **Total** | **3099** | **188390** | **164.50** | **4085** | **255430** | **159.93** |
|  | | | | | | |
| Facility | **Pre-intervention 10.1.21 - 3.31.22** | | | **Intervention 4.1.22 - 7.31.22** | | |
| Total Orders | Patient days | Order rate per 10,000 patient days | Total Orders | Patient days | Order rate per 10,000 patient days |
| C | 602 | 43854 | 137.27 | 408 | 28183 | 144.77 |
| D | 606 | 49523 | 122.37 | 335 | 28155 | 118.98 |
| E | 410 | 23175 | 176.91 | 237 | 14866 | 159.42 |
| F | 440 | 26907 | 163.53 | 216 | 14117 | 153.01 |
| G | 373 | 32609 | 114.39 | 153 | 20578 | 74.35 |
| H | 178 | 18882 | 94.27 | 120 | 12904 | 92.99 |
| I | 246 | 32916 | 74.74 | 117 | 20369 | 57.44 |
| J | 199 | 13080 | 152.14 | 110 | 8111 | 135.62 |
| K | 229 | 4037 | 567.25 | 107 | 1810 | 591.16 |
| L | 186 | 17802 | 104.48 | 70 | 8351 | 83.82 |
| M | 103 | 7352 | 140.10 | 62 | 4188 | 148.04 |
| N | 95 | 4760 | 199.58 | 44 | 2547 | 172.75 |
| O | 18 | 2332 | 77.19 | 16 | 977 | 163.77 |
| P | 30 | 2300 | 130.43 | 12 | 1143 | 104.99 |
| Q | 11 | 36089 | 3.05 | 9 | 21258 | 4.23 |
| **Total** | **3726** | **315618** | **118.05** | **2016** | **187557** | **107.49** |

# **Supplemental Table S6: Completed test rate per 10,000 patient days of *Clostridioides difficile* before and after implementation of a 24-hour autocancellation**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Facility | **Pre-intervention 5.1.21 - 10.31.21** | | | **Intervention 11.1.22 - 7.31.22** | | |
| Total completed tests | Patient Days | Completed test rate per 10,000 patient days | Total completed tests | Patient Days | Completed test rate per 10,000 patient days |
| A | 1164 | 114578 | 101.59 | 1236 | 153575 | 80.48 |
| B | 873 | 73812 | 118.27 | 1017 | 101855 | 99.85 |
| **Total** | **2037** | **188390** | **108.13** | **2253** | **255430** | **88.20** |
|  | | | | | | |
| Facility | **Pre-intervention 10.1.21 - 3.31.22** | | | **Intervention 4.1.22 - 7.31.22** | | |
| Total completed tests | Patient Days | Completed test rate per 10,000 patient days | Total completed tests | Patient Days | Completed test rate per 10,000 patient days |
| C | 432 | 43854 | 98.51 | 268 | 28183 | 95.09 |
| D | 377 | 49523 | 76.13 | 202 | 28155 | 71.75 |
| E | 242 | 23175 | 104.42 | 132 | 14866 | 88.79 |
| F | 215 | 26907 | 79.90 | 105 | 14117 | 74.38 |
| G | 183 | 32609 | 56.12 | 103 | 20578 | 50.05 |
| H | 85 | 18882 | 45.02 | 67 | 12904 | 51.92 |
| I | 169 | 32916 | 51.34 | 85 | 20369 | 41.73 |
| J | 123 | 13080 | 94.04 | 69 | 8111 | 85.07 |
| K | 127 | 4037 | 314.59 | 58 | 1810 | 320.44 |
| L | 141 | 17802 | 79.20 | 52 | 8351 | 62.27 |
| M | 74 | 7352 | 100.65 | 39 | 4188 | 93.12 |
| N | 62 | 4760 | 130.25 | 33 | 2547 | 129.56 |
| O | 10 | 2332 | 42.88 | 10 | 977 | 102.35 |
| P | 20 | 2300 | 86.96 | 5 | 1143 | 43.74 |
| Q | 9 | 36089 | 2.49 | 8 | 21258 | 3.76 |
| **Total** | **2269** | **315618** | **71.89** | **1236** | **187557** | **65.90** |

# **Supplemental Figure S1: Timing of retesting of autocanceled *Clostridioides difficile* orders during the intervention period**

# **Supplemental Table S7: 30-day retesting outcomes following autocanceled *Clostridioides difficile* orders during the intervention period**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Facility** | **Retested positive** | | **Reordered – Not collected** | | **Retested negative** | | **Not retested** | | **Duplicate order** | | **Total** |
| A | 23 | (5.8%) | 32 | (8.0%) | 83 | (20.9%) | 212 | (53.3%) | 48 | (12.1%) | 398 |
| B | 8 | (3.1%) | 26 | (10.2%) | 56 | (22.0%) | 149 | (58.7%) | 15 | (5.9%) | 254 |
| D | 0 | (0.0%) | 1 | (1.2%) | 10 | (12.0%) | 72 | (86.7%) | 0 | (0.0%) | 83 |
| C | 1 | (1.2%) | 0 | (0.0%) | 21 | (25.9%) | 59 | (72.8%) | 0 | (0.0%) | 81 |
| F | 1 | (1.7%) | 3 | (5.0%) | 7 | (11.7%) | 36 | (60.0%) | 13 | (21.7%) | 60 |
| E | 2 | (4.3%) | 4 | (8.7%) | 8 | (17.4%) | 32 | (69.6%) | 0 | (0.0%) | 46 |
| K | 2 | (5.0%) | 3 | (7.5%) | 4 | (10.0%) | 31 | (77.5%) | 0 | (0.0%) | 40 |
| H | 3 | (11.1%) | 0 | (0.0%) | 5 | (18.5%) | 19 | (70.4%) | 0 | (0.0%) | 27 |
| J | 2 | (8.0%) | 1 | (4.0%) | 4 | (16.0%) | 18 | (72.0%) | 0 | (0.0%) | 25 |
| I | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 18 | (100.0%) | 0 | (0.0%) | 18 |
| M | 0 | (0.0%) | 0 | (0.0%) | 2 | (12.5%) | 14 | (87.5%) | 0 | (0.0%) | 16 |
| G | 1 | (6.7%) | 0 | (0.0%) | 2 | 13.3% | 12 | (80.0%) | 0 | (0.0%) | 15 |
| N | 0 | (0.0%) | 0 | (0.0%) | 2 | (20.0%) | 8 | (80.0%) | 0 | (0.0%) | 10 |
| L | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 6 | (100.0%) | 0 | (0.0%) | 6 |
| P | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 5 | (100.0%) | 0 | (0.0%) | 5 |
| O | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 5 | (100.0%) | 0 | (0.0%) | 5 |
| Q | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 1 | (100.0%) | 0 | (0.0%) | 1 |
| **Total** | **43** | **(3.9%)** | **70** | **(6.4%)** | **204** | **(18.7%)** | **697** | **(63.9%)** | **76** | **(7.0%)** | **1090** |

*Note: intervention period for facilities A and B, 11/1/2021-7/31/2022; intervention period for facilities C-Q, 4/1/2022-7/31/2022.*

# **Supplemental Table S8: Reasons *Clostridioides difficile* autocanceled orders did not have a retest within 30 days**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Facility** | **Alternative diagnosis** | | **Diarrhea resolved**  **/improved** | | **Discharged before collection** | | **Laxative use** | | **On tube feeds** | | **Other** | | **Recent *C. diff* test** | | **Treated without collection** | | **Total** |
| A | 24 | (11.3%) | 168 | (79.2%) | 5 | (2.4%) | 4 | (1.9%) | 2 | (1.9%) | 1 | (0.5%) | 5 | (2.4%) | 3 | (1.4%) | 212 |
| B | 23 | (15.4%) | 110 | (73.8%) | 4 | (2.7%) | 1 | (0.7%) | 1 | (0.7%) | 3 | (2.0%) | 4 | (2.7%) | 3 | (2.0%) | 149 |
| D | 16 | (22.2%) | 44 | (61.1%) | 1 | (1.4%) | 0 | (0.0%) | 2 | (0.0%) | 9 | (12.5%) | 0 | (0.0%) | 0 | (0.0%) | 72 |
| C | 10 | (16.9%) | 38 | (64.4%) | 2 | (3.4%) | 2 | (3.4%) | 0 | (3.4%) | 7 | (11.9%) | 0 | (0.0%) | 0 | (0.0%) | 59 |
| F | 7 | (19.4%) | 29 | (80.6%) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 36 |
| E | 5 | (15.6%) | 15 | (46.9%) | 0 | (0.0%) | 2 | (6.3%) | 2 | (6.3%) | 8 | (25.0% | 0 | (0.0%) | 0 | (0.0%) | 32 |
| K | 5 | (16.1%) | 21 | (67.7%) | 4 | (12.9%) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 1 | (3.2%) | 31 |
| H | 9 | (47.4%) | 7 | (36.8%) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 3 | (15.8%) | 19 |
| I | 1 | (5.6%) | 13 | (72.2%) | 2 | (11.1%) | 0 | (0.0%) | 0 | (0.0%) | 1 | (5.6%) | 1 | (5.6%) | 0 | (0.0%) | 18 |
| J | 8 | (44.4%) | 7 | (38.9%) | 1 | (5.6%) | 0 | (0.0%) | 1 | (0.0%) | 0 | (0.0%) | 1 | (5.6%) | 0 | (0.0%) | 18 |
| M | 1 | (7.1%) | 12 | (85.7%) | 1 | (7.1%) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 14 |
| G | 3 | (25.0%) | 5 | (41.7%) | 1 | (8.3%) | 0 | (0.0%) | 1 | (0.0%) | 0 | (0.0%) | 2 | (16.7%) | 0 | (0.0%) | 12 |
| N | 1 | (12.5%) | 5 | (62.5%) | 0 | (0.0%) | 1 | (12.5%) | 0 | (12.5%) | 0 | (0.0%) | 0 | (0.0%) | 1 | (12.5%) | 8 |
| L | 0 | (0.0%) | 6 | (100.0%) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 6 |
| P | 0 | (0.0%) | 4 | (80.0%) | 1 | (20.0%) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 5 |
| O | 0 | (0.0%) | 5 | (100.0%) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 5 |
| Q | 0 | (0.0%) | 1 | (100.0%) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 0 | (0.0%) | 1 |
| **Total** | **113** | **(16.2%)** | **490** | **(70.3%)** | **22** | **(3.2%)** | **10** | **(1.4%)** | **9** | **(1.3%)** | **29** | **(4.2%)** | **13** | **(1.9%)** | **11** | **(1.6%)** | **697** |

*Note: intervention period for facilities A and B, 11/1/2021-7/31/2022; intervention period for facilities C-Q, 4/1/2022-7/31/2022*